| 0.084 Data as of 12:16pm ET |  +0.002 / +2.44%Today’s Change | 0.06 Today|||52-Week Range 0.26 | -55.79% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $10.6M |
Company Description
Cardium Therapeutics, Inc. is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses having the potential to address significant unmet medical needs, and definable pathways to commercialization, partnering and other economic monetization. The company conducts its business through three operating units: Cardium Biologics, Tissue Repair Co., and MedPodium Health Sciences. The Cardium Biologics operating unit engages in developing innovative cardiovascular product candidates. The Tissue Repair Co., a wholly-owned subsidiary, engages in developing and commercializing a late-stage line of regenerative medicine product candidates. The MedPodium Health Sciences, also a subsidiary, involves in developing a line of nutraceuticals and other healthy lifestyle products. Cardium Therapeutics was founded by Christopher J. Reinhard and Tyler M. Dylan-Hyde on December 22, 2003 and is headquartered in San Diego, CA
Employees
Shareholders
| Individual stakeholders | 5.98% |
| Other institutional | 5.85% |
| Mutual fund holders | 0.51% |
Top Executives
| Christopher J. Reinhard, MBA | Chairman, President, CEO & Treasurer |
| Dennis M. Mulroy, CPA | Chief Financial Officer |
| Gabor M. Rubanyi, MD, PhD | Chief Scientific Officer |
| Ted Williams | VP-Manufacturing & Technical Operations |
| Tyle M. Dylan-Hyde, PhD | Secretary, Director, Chief Business Officer & EVP |
.
